- Abstract:
-
BACKGROUND: There is now increasing evidence that a constitutive expression of cyclooxygenase (COX)-2 plays a role in the development and progression of malignant epithelial tumors. Expression of COX-2 is seen in 93% of melanomas, as determined by immunohistochemistry. Temozolomide (TMZ) has demonstrated activity against melanoma and has been investigated as single agent or in combination. We designed a phase II study to assess the efficacy and toxicity of the combination of TMZ and celecoxib...
Expand abstract - Publication status:
- Published
- Journal:
- Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
- Volume:
- 17
- Issue:
- 12
- Pages:
- 1835-1841
- Publication date:
- 2006-12-05
- DOI:
- EISSN:
-
1569-8041
- ISSN:
-
0923-7534
- URN:
-
uuid:7f974fd2-32e0-4148-adfa-205faef6cb3a
- Source identifiers:
-
119685
- Local pid:
- pubs:119685
- Copyright date:
- 2006
Journal article
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Actions
Authors
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record